drugset / Trial / NCT02099539
QUILT-3.005: A Study of N-803 in Patients With Relapsed or Refractory Multiple Myeloma
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This is a Phase I/II, open-label, multi-center, competitive enrollment and dose escalation study of N-803 in patients with relapsed or refractory multiple myeloma.
Timeline
- Start
- 2014-10-06
- Primary completion
- 2018-06-19
- Completion
- 2018-06-19
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | N-803 | Protein / enzyme biologic | 1 ug/kg | Intravenous |
| Subject | N-803 | Protein / enzyme biologic | 3 ug/kg | Intravenous |
| Subject | N-803 | Protein / enzyme biologic | 6 ug/kg | Intravenous |
| Subject | N-803 | Protein / enzyme biologic | 10 ug/kg | Intravenous |
| Subject | N-803 | Protein / enzyme biologic | 15 ug/kg | Intravenous |